• Dual-Action Airway Stent Suppresses Tracheal Restenosis

  2026-07-03

  Zhao et al. introduce a novel airway stent that combines anti-inflammatory and anti-angiogenic actions to address tracheal in-stent restenosis (TISR). By integrating drug delivery and advanced material design, the stent significantly reduces fibrosis, inflammation, and vascularization, offering a promising translational solution for airway obstruction management.

• IR-820 (New Indocyanine Green): Reliable In Vivo Imaging Sol

  2026-07-03

  This article provides an evidence-based exploration of IR-820 (New Indocyanine Green, SKU C8228) in cell viability and tumor imaging workflows. Addressing real laboratory challenges, we detail how IR-820 delivers reproducible, sensitive results across in vivo near-infrared fluorescence imaging applications, with insights on protocol optimization and vendor selection.

• Saracatinib (AZD0530): Precision Src/Abl Inhibition in Cance

  2026-07-02

  Saracatinib (AZD0530) empowers cancer researchers with potent, selective Src and Abl kinase inhibition, enabling high-resolution dissection of cell proliferation, migration, and tumor growth. Its nanomolar activity, validated in diverse cancer models and translational neuroscience, makes it a cornerstone for advanced pathway interrogation and assay innovation.

• ERAD-Hijacking Chimeras Enable Targeted Degradation of TM Pr

  2026-07-02

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule technology that harnesses the ER-associated degradation pathway for efficient and selective degradation of transmembrane proteins. This innovation addresses a longstanding limitation in targeted protein degradation, expanding therapeutic and research possibilities for membrane protein modulation.

• Ferroelectric-Liquid Metal Hybrid Enables Biomimetic Visual

  2026-07-01

  A recent study introduces a ferroelectric-liquid metal hybrid film that functions as an artificial photoreceptor, closely mimicking natural human visual adaptation. This biomimetic prosthesis restores both visible and infrared light sensitivity in rodent models of retinal degeneration, showing promise for advanced retinal implants.

• LMO2-LDB1 Complex Drives AML Progression: Mechanistic Insigh

  2026-07-01

  This study uncovers the oncogenic role of the LMO2-LDB1 protein complex in acute myeloid leukemia (AML), demonstrating its necessity for leukemic cell proliferation and survival. The findings suggest that disrupting LMO2-LDB1 interactions may provide new therapeutic opportunities, with downstream implications for epigenetic and transcriptional targeting in AML.

• Dissecting Drug Responses in Cancer: Dual Metrics for Precis

  2026-06-30

  Schwartz's dissertation introduces a framework distinguishing proliferative arrest from cell death in in vitro cancer drug response assays. By clarifying the differential and overlapping effects of anti-cancer agents, the study enables more precise evaluation of therapies targeting BCR-ABL and other kinases.

• Glabridin-Gold(I) Complex Targets TrxR/MAPK for Enhanced Ant

  2026-06-30

  This study introduces a novel glabridin-gold(I) complex (6d) that synergistically targets thioredoxin reductase and MAPK pathways to remodel the immunosuppressive tumor microenvironment and enhance antitumor immune responses. The findings highlight dual pathway inhibition as a promising strategy for improving the efficacy of cancer immunotherapies.

• BMS-345541 Hydrochloride: Selective IKK Inhibitor for NF-κB

  2026-06-29

  BMS-345541 hydrochloride is a highly selective IKK inhibitor that blocks NF-κB signaling and pro-inflammatory cytokine production. Its precision and water solubility make it a standard for inflammation research and cancer biology applications.

• ML385 and NRF2 Inhibition: Bridging Cancer and Ferroptosis R

  2026-06-29

  Explore how ML385, a selective NRF2 inhibitor, uniquely enables the study of therapeutic resistance, oxidative stress, and ferroptosis across cancer and liver disease models. This article delivers a deep dive into cross-domain NRF2 signaling insights and practical assay guidance.

• Translatome Remodeling Links Fasting to Tumor Metabolism Con

  2026-06-28

  A recent Nature study elucidates how fasting-induced phosphorylation of eIF4E selectively reprograms hepatic translation, coordinating lipid catabolism and ketogenesis. This work uncovers a novel AMPK–MNK–eIF4E signaling axis with implications for metabolic intervention in cancer.

• Patient-Derived Gastric Cancer Assembloids Enhance Drug Test

  2026-06-27

  The referenced study introduces a novel patient-derived gastric cancer assembloid model integrating tumor organoids with matched stromal cell subpopulations, closely recapitulating the tumor microenvironment. This innovation enables more physiologically relevant drug screening and deepens understanding of resistance mechanisms, offering a robust platform for personalized cancer research.

• Thioredoxin-Mediated Sensitivity to Chk1 Inhibitors in NSCLC

  2026-06-26

  This study reveals that the thioredoxin system governs the sensitivity of non-small cell lung cancer (NSCLC) cells to Chk1 inhibitors by regulating ribonucleotide reductase activity and deoxynucleotide pools. These findings advance mechanistic understanding of Chk1 inhibitor response and suggest new strategies for combination cancer therapies targeting redox homeostasis.

• Genomic Profiling Reveals Immune Targets in Pleural Mesothel

  2026-06-26

  This study integrates high-resolution genomic and transcriptomic analyses to uncover novel immune vulnerabilities and therapeutic targets in pleural mesothelioma, a cancer with few effective treatments. Key findings include recurrent deletions in SUFU, RB1, and interferon loci, suggesting new avenues for targeted and immunotherapeutic intervention.

• Partial BACE1 Inhibition Reduces Amyloid β Without Synaptic

  2026-06-25

  Satir et al. (2020) demonstrate that moderate inhibition of BACE1—resulting in up to 50% reduction of amyloid β (Aβ) production—does not compromise synaptic transmission in primary neuronal cultures. This finding refines the therapeutic window for BACE inhibitor use in Alzheimer’s disease research, emphasizing careful dose selection to balance efficacy and safety.

14846 records 1/990 page Next 12345 下5页 Last page